|Bid||5.19 x 900|
|Ask||5.45 x 1100|
|Day's Range||5.11 - 5.76|
|52 Week Range||3.12 - 20.27|
|Beta (5Y Monthly)||3.14|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 11, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||16.44|
Medical aesthetics company Evolus (EOLS) has experienced dramatic volatility recently, but the reason why remains a mystery.“We have received many questions on today's large move in Evolus shares, up >50% earlier and now +~20% on very heavy volumes” wrote Mizuho Securities’ Vamil Divan on May 22.“We do not have any specific insights or explanations, but provide here our thoughts on some possible drivers investors have been asking us about” he added. The stock closed Friday’s trading up 10%, and continued with a 5% gain after-hours.One possible option is short covering ahead of an ITC decision, although Divan writes that this ‘seems excessive’ given that a preliminary decision from the ITC is expected by June 5, with a final decision due in October.“One of the main overhangs on EOLS shares this year has been the ongoing US International Trade Commission hearing between Medytox and Daewoong and implications that the decision may have on Evolus' ability to commercialize Jeuveau in the US” Divan explains.But, he adds, “it is not clear to us why such a large move would suddenly occur today, as opposed to earlier this week or between now and early June.”He also sees a Korean ruling on Medytox as having little material impact on Evolus or sales of Evolus' Jeuveau in the US, where the vast majority of Evolus' value is coming from.And while the most important factor for Evolus is a reopening of physician practices where customers can start receiving facial toxin treatments again there was no significant shift on Friday that would necessarily change investor sentiment in such a meaningful way.“Fundamentally, our views on the stock have not changed” says Divan, as he maintained his buy rating and $8 price target on Evolus stock (79% upside potential).He sees Evolus as having a potentially unique place in the attractive aesthetics market, but assumes it will take time for the market to return to anything close to normal following the Covid-19 pandemic and resulting economic fallout.Jeuveau will still be the newest toxin on the market when the market starts to recover, says Divan, and Evolus can further leverage their digital platform and help improve product affordability for patients and improve profitability for providers.Despite the recent rally, shares have still plunged 63% year-to-date, and the overall analyst consensus remains a cautiously optimistic Moderate Buy. The average analyst price target stands at $8. (See Evolus stock analysis on TipRanks).Related News: European Launch of Kylie Skin Boosts Coty Stock by 15% Agilent Up 5% On Solid Revenue Beat, But Top Analysts Stay Cautious Catalysts for Peloton Extend Long Past COVID-19, Says Top Analyst
Market forces rained on the parade of Evolus, Inc. (NASDAQ:EOLS) shareholders today, when the analysts downgraded...
With me today are David Moatazedi, President and Chief Executive Officer; Lauren Silvernail, Chief Financial Officer and EVP, Corporate Development; Mike Jafar, Chief Marketing Officer; and Rui Avelar, Chief Medical Officer and Head of R&D. In our remarks today, we will include statements that are considered forward-looking statements within the meaning of United States security laws.
NEWPORT BEACH, Calif., May 11, 2020 -- Evolus, Inc. (Nasdaq: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products,.
NEWPORT BEACH, Calif., May 06, 2020 -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products,.
Evolus, Inc. (EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced a pre-emptive plan to support the U.S. aesthetic neurotoxin market in light of the COVID-19 pandemic. Since launch, the combination of our experienced sales force and uniquely designed digital platform has enabled the rapid market uptake of Jeuveau®. “As aesthetic practices begin to re-open, we plan to introduce a new stimulus program, executed through our fully integrated digital platform, to address customer profitability and consumer affordability.”
Market forces rained on the parade of Evolus, Inc. (NASDAQ:EOLS) shareholders today, when the analysts downgraded...
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 4) * 89bio Inc (NASDAQ: ETNB) * Arcus Biosciences Inc (NYSE: RCUS) * Arcturus Therapeutics Ltd (NASDAQ: ARCT)(announced a partnership with Duke-NUS Medical School to develop a COVID-19 vaccine for Singapore) * Cue Biopharma Inc (NASDAQ: CUE) * IGM Biosciences Inc (NASDAQ: IGMS) * Inovio Pharmaceuticals Inc (NASDAQ: INO) * Ocular Therapeutix Inc (NASDAQ: OCUL)(reacted to its preliminary fourth-quarter results and interim data from a Phase 1 study evaluating its eye implant OTX-TKI in patients with wet age-related macular degeneration) * Quest Diagnostics Inc (NYSE: DGX) * Regeneron Pharmaceuticals Inc (NASDAQ: REGN)(CEO Leonard Schleifer reportedly told CNBC the company hopes to produce COVID-19 treatment candidate that could be ready for human testing by August) * Revolution Medicines Inc (NASDAQ: RVMD) (IPOed mid-February) * SpringWorks Therapeutics Inc (NASDAQ: SWTX) * Syndax Pharmaceuticals Inc (NASDAQ: SNDX)(reacted to the company's fourth-quarter results) * Syneos Health Inc (NASDAQ: SYNH) * Viela Bio Inc (NASDAQ: VIE)Down In The Dumps (Biotech Stocks Hitting 52-week lows on March 4) * Alterity Therapeutics Ltd (NASDAQ: ATHE) * AngioDynamics, Inc. (NASDAQ: ANGO) * Aptevo Therapeutics Inc (NASDAQ: APVO) * CASI Pharmaceuticals Inc (NASDAQ: CASI) * Enlivex Therapeutics Ltd (NASDAQ: ENLV) * Evogene Ltd (NASDAQ: EVGN)(reacted to fourth-quarter results) * Evolus Inc (NASDAQ: EOLS)(reacted to comments by Korean drug maker Medytox about an ITC case brought up by the company against Daewoong and partner Evolus on intellectual property related to Medytox' botulinum toxin) * Mylan NV (NASDAQ: MYL) * Orthofix Medical Inc (NASDAQ: OFIX) * Passage Bio Inc (NASDAQ: PASG)(IPOed last week) * Titan Medical Inc. (NASDAQ: TMDI)See also: Attention Biotech Investors: Mark Your Calendar For These March PDUFA Dates Stocks In Focus Co-Diagnostics' COVID-19 Detection Kit Demand Surges Co-Diagnostics Inc (NASDAQ: CODX) said demand, both domestic and international, surged for its COVID-19 detection kits in recent weeks, leading to increased product shipments. The increase comes after the FDA changed its policy Feb. 20 and the number of cases testing positive for the disease burgeoned worldwide.The stock was surging 27.17% to $15.26 in pre-market trading.Castle Biosciences Gets First Patent For Skin Cancer Gene Expression Profile Test Skin cancer diagnostic company Castle Biosciences Inc (NASDAQ: CSTL) said the U.S. patent office has issued it the first U.S. patent related to the DecisionDx -Melanoma gene expression profile test for patients with cutaneous melanoma.FDA Accepts Trevena's Resubmitted NDA for Pain Drug Trevena Inc (NASDAQ: TRVN) said the FDA has acknowledged the receipt of and accepted the resubmitted NDA for intravenous oliceridine, its lead investigational asset, for the management of moderate-to-severe acute pain. The PDUFA date has been set for Aug. 7.In pre-market trading, shares were rising 12.35% to 91 cents.Can-Fite To Explore Treatment For COVID-19 Can-Fite BioPharma Ltd. (NASDAQ: CANF) said it is exploring a collaboration to explore if its investigational asset Piclidenoson, being evaluated for autoimmune inflammatory disease, is effective against coronavirus following reports that rheumatoid arthritis drugs have been introduced for the treatment of the same.The stock was jumping 26.28% to $1.97 in pre-market trading.RA Medical Says NYSE Accepts Plan to Regain Compliance RA Medical Systems Inc (NYSE: RMED) said the NYSE has accepted the company's business plan to regain compliance with the NYSE listing standards. Late last year, the company was notified by the NYSE regarding flouting of listing standards pertaining to average market capitalization being less than $50 million over a recent consecutive 30 days.MacroGenomics' Chief Medical Officer Resigns to Pursue Another Opportunity MacroGenics Inc (NASDAQ: MGNX) announced the resignation of Jon Wigginton as its SVP, Clinical Development & Chief Medical Officer, effective March 27, as he pursues a new opportunity. The role will be assigned on an interim basis to Ezio Bonvini, who is currently serving as SVP, Research and Chief Scientific Officer, the company said.Morphosys To Issue Additional Shares For Subscription By Incyte As Part of Tafasitamab Licensing Deal Morphosys Ag (NASDAQ: MOR) said its Management Board has resolved to increase the share capital of the company by issuing 907,441 new ordinary shares from the authorized capital to facilitate purchase of 3.63 million ADSs by Incyte Corporation (NASDAQ: INCY). The newly issued shares represent about 2.84% of the registered share capital of MorphoSys prior to the consummation of the capital increase.View more earnings on TRVNIncyte's purchase of ADSs amounting to $150 million or $41.32 per ADS is part of the consideration due to MorphoSys for the former acquiring licensing rights to develop and commercialize the latter's investigational compound tafasitamab.In pre-market trading, MorphoSys shares were slipping 3.70% to $28.89.Earnings Specialty pharma company Opiant Pharmaceuticals Inc (NASDAQ: OPNT), which develops treatment for treating addictions and drug overdose, reported fourth-quarter revenues of $7.7 million compared to $4.8 million in the fourth quarter of 2018. The company reversed to a profit of 20 cents per share from a loss of $2.49 per share last year, while analysts had estimated a loss of $2.13 per share, on average.The stock rallied 17.09% to $13.70 in after-hours trading.Offerings BridgeBio Pharma Inc (NASDAQ: BBIO) priced the upsized offering of $475 million aggregate principal amount of 2.50% convertible senior notes due 2027 in a private offering to qualified institutional buyers. The company said the notes will bear interest at a rate of 2.50% per year, payable semi-annually in arrears on March 15 and Sept. 15 of each year. Beginning Sept. 15, 2020.The company estimates to raise net proceeds of about $463.7 million from the offering.On The Radar Earnings * Arbutus Biopharma Corp (NASDAQ: ABUS) (before the market open) * BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) (before the market open) * Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT) (before the market open) * Xtant Medical Holdings Inc (NYSE: XTNT) (before the market open) * Fulcrum Therapeutics Inc (NASDAQ: FULC) (before the market open) * Syros Pharmaceuticals Inc (NASDAQ: SYRS) (before the market open) * Obseva SA (NASDAQ: OBSV) (before the market open) * OptiNose Inc (NASDAQ: OPTN) (before the market open) * Caladrius Biosciences Inc (NASDAQ: CLBS) (after the close) * Eton Pharmaceuticals Inc (NASDAQ: ETON) (after the close) * BioNano Genomics Inc (NASDAQ: BNGO) (after the close) * Corvus Pharmaceuticals Inc (NASDAQ: CRVS) (after the close) * Eloxx Pharmaceuticals Inc (NASDAQ: ELOX) (after the close)See more from Benzinga * GenMark Spikes Higher On COVID-19 Test Kit Shipment * The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And More * How The COVID-19 Outbreak Is Benefiting Biotech Investors(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
The Judge assigned to the ITC case is not obligated to accept a staff attorney’s position on the facts, and it’s fairly common for the Judge and the staff attorney to disagree on substantive matters. Evolus and Daewoong remain confident in the strength of our intellectual property and will continue to vigorously defend it through the entirety of the ITC process. In addition, numerous claims have been made in the Korean press regarding settlement discussions related to the ITC proceedings.
NEWPORT BEACH, Calif., March 03, 2020 -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products,.
Q4 2019 Net Revenue $19.5 Million, Up from $13.2 Million in Q3 2019 Jeuveau® Achieved Number Three Unit Share Position in the U.S. in 20191 Launched Evolux™;.
NEW YORK, NY / ACCESSWIRE / February 25, 2020 / Evolus, Inc. (NASDAQ:EOLS) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on February 25, 2020 at 8:00 AM ...
NEWPORT BEACH, Calif., Feb. 13, 2020 -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products,.
NEWPORT BEACH, Calif., Feb. 12, 2020 -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products,.
When shares fall, investor focus locks in. The first instinct, for some, is to avoid the name entirely after the investing alarm bells have been sounded. Sure, dropping share prices can indicate that there’s a deeper issue hampering the company such as weak fundamentals or headwinds that appear unbeatable. Having said that, this isn’t the case for every stock that has seen its share price take a hit.Wall Street pros remind investors that while not all beaten-down names are primed for a recovery, others offer investors a unique buying opportunity, with their current share prices reflecting an attractive entry point.So, how are investors supposed to know when it’s time to buy the dip? TipRanks' Stock Screener tool helped us zero in on 3 compelling stocks, specifically in the healthcare industry, by filtering our search results by sector, analyst consensus and price target upside. While these names have taken a beating, each has generated substantial bullish sentiment from the analysts and boasts massive upside potential from current levels. Let’s dive right in.Sientra, Inc. (SIEN)First up, we have Sientra, a company that is best known for producing implants and other products for breast augmentation or reconstruction procedures. While the healthcare name has started off 2020 down 25%, Wall Street analysts see better days on the horizon.The recent weakness actually follows a relatively solid preliminary fourth quarter revenue announcement. On January 13, the company told investors that miraDry’s better-than-expected performance drove a modest revenue beat. However, the breast segment missed the mark and there are still some concerns regarding its balance sheet as its cost restructuring efforts won't generate cash flow benefits until 2021.That being said, Leerink Partners analyst Richard Newitter points out that the breast segment still achieved 20%-plus growth, and his conversation with SIEN management actually implies that its breast implant business accelerated. Additionally, he stated that if one-time events are excluded, cash burn improved.As a result, he argues that the pullback is “too excessive.“ “We've seen SIEN's stock react unexplainably negative in the past to otherwise solid results (i.e., initially after a 2Q19 beat) only to recover shortly thereafter. We think this will prove to be one of those situations and reiterate our OP rating as we continue to believe SIEN's valuation discount is disconnected from an over 20% top-line growth profile,” he explained.With Newitter anticipating that its OPUS implant launch and miraDry sales growth will also help fuel a recovery, it makes sense that he still sides with the bulls. To this end, the five-star analyst reiterated an Outperform recommendation and $13 price target. Should this target be met, shares could be in for a 93% twelve-month gain. (To watch Newitter’s track record, click here)What does the rest of the Street think? Based on 100% Street support, or a total of 6 bullish calls assigned in the last three months, the consensus rating is a unanimous Strong Buy. The $13.20 average price target puts the upside potential above Newitter’s forecast at 96%. (See Hercules Capital’s stock analysis at TipRanks)ViewRay, Inc. (VRAY)ViewRay is focused on giving clinicians new and more effective ways to treat cancer using radiation. Its approach uses MRI-based technology to provide real-time imaging that clearly defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment. With this groundbreaking offering, why have shares dipped 25% year-to-date?The share price decline comes on the heels of its preliminary Q4 results. VRAY announced that it expects quarterly sales of $17 million, landing very close to the consensus estimate. However, new orders largely disappointed, with this figure coming in at $21 million. As this is down from $49 million in the prior-year quarter, it’s no wonder investors have been concerned. It also didn’t help that VRAY burned through about $3 million in cash.That isn’t to say investors should give up on the healthcare name. Piper Sandler’s Matthew O'Brien did acknowledge the result was unexpected “as momentum in the order book appeared to have been building with eight orders (three upgrades) last quarter.” However, he argues that the soft order figure is indicative of “standard lumpiness capital equipment sales”, which should improve in the coming quarters.“Although we do not expect this to be the last bump in the road, we remain highly confident in the utility of the MRIdian as the best technology to treat cancer patients, and we believe it will yield significant share-taking over the next couple of years,” O’Brien commented. He added, “We believe today’s dip represents a buying opportunity to investors willing to weather some quarterly volatility...”As recent investments from heavyweights Medtronic and Elekta boosted its capital, VRAY should be able to improve system install times as well as access potential hospital targets for the MRIdian system. Based on all of these factors, the five-star analyst maintained an Overweight rating and $6 price target. At this target, shares could soar 89% in the next twelve months. (To watch O’Brien’s track record, click here)Like O’Brien, other Wall Street analysts are staying on board. 6 Buys and a single Hold issued in the last three months add up to a Strong Buy analyst consensus. In addition, the $6.71 average price target implies 112% upside potential. (See ViewRay stock analysis on TipRanks)Evolus, Inc. (EOLS) Evolus is giving people a reason to smile, offering an FDA-approved injectable medicine to improve the appearance of frown lines. Despite shedding 19% of its value since the beginning of 2020, one analyst believes that EOLS will be able to turn investors’ frowns upside down.Marc Goodman of Leerink Partners wrote in a recent note that he suggests “aggressive buying of EOLS shares” after the stock’s tumble. Shares set off on a downward trajectory after it pre-announced its fourth quarter results. Total sales could land within the range of $18.5 million to $19.5 million, compared to the $16.1 million consensus estimate. In addition, the amount of purchasing accounts is expected to increase substantially from about 2,000 in the third quarter to almost 3,500 in the fourth quarter.“We are baffled by the weakness today and view as a great buying opportunity. In our view, commercial execution by this management team has been excellent so far and the sales ramp is very encouraging. From a ‘back of the envelope’ view we simplistically say that if this is just a $250 million peak sales product, these types of aesthetics assets trade for at least 5x sales, and thus that implies a valuation at least 3x where the stock currently trades,” Goodman noted.Even though the four-star analyst points out that investors have been worried about the lockup period for Alphaeon, which owns 26%, and the ITC litigation, he doesn’t think that either hampers its long-term growth prospects.Bearing this in mind, he kept his Outperform rating and $25 price target as is. This target conveys his confidence in Evolus’ ability to climb 154% higher in the twelve months ahead. (To watch Goodman’s track record, click here)Looking at the consensus breakdown, 6 Buys, 1 Hold and 1 Sell make the consensus rating a Moderate Buy. It should be noted, though, that the average price target of $26.88 indicates a whopping 173% potential twelve-month gain. (See Evolus stock analysis on TipRanks)
NEWPORT BEACH, Calif., Jan. 27, 2020 -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products,.
Evolus, Inc. (EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced its preliminary unaudited revenues for the fourth quarter and full year ended December 31, 2019 and cash position at December 31, 2019. The preliminary unaudited results described in this press release are estimates only and are subject to revision until the company reports its full financial results for the fourth quarter and full year 2019. Cash, cash equivalents and short-term investments were $129.8 million at December 31, 2019.
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...
Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips or bumps on the charts, usually don't make them change their opinion towards a company. This time it may be different. During the fourth quarter of 2018 we observed increased volatility and a 20% drop in […]
NEWPORT BEACH, Calif., Nov. 07, 2019 -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products,.
The big shareholder groups in Evolus, Inc. (NASDAQ:EOLS) have power over the company. Institutions will often hold...
Evolus, Inc. (EOLS) (“Evolus”) announced today the pricing of its public offering of 5,217,000 shares of its common stock at a public offering price of $13.00 per share, before underwriting discounts and commissions. Evolus is expected to receive net proceeds of approximately $63.5 million, after deducting underwriting discounts and commissions and estimated offering expenses. In addition, Evolus has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional 782,550 shares at the public offering price, less the underwriting discounts and commissions.
Evolus, Inc. (EOLS) (“Evolus”) announced today that it has commenced a proposed underwritten public offering, subject to market and other conditions, to issue and sell shares of its common stock. Evolus expects to grant the underwriters of the offering an option for a period of 30 days to purchase up to an additional 15% of the shares of its common stock offered in the public offering. All of the shares in the offering are to be sold by Evolus.
Jeuveau® Generated $13.2 Million in U.S. Net Revenue in Q3 2019; up from $2.3 Million in Q2 2019 J.E.T. Enrolled Accounts Drove 90% of Q3 Revenue Jeuveau®.
While the market driven by short-term sentiment influenced by the accomodative interest rate environment in the US, increasing oil prices and deteriorating expectations towards the resolution of the trade war with China, many smart money investors kept their cautious approach regarding the current bull run in the second quarter and hedging or reducing many of […]